These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19826047)

  • 21. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome.
    Boultwood J; Fidler C; Lewis S; MacCarthy A; Sheridan H; Kelly S; Oscier D; Buckle VJ; Wainscoat JS
    Blood; 1993 Nov; 82(9):2611-6. PubMed ID: 8219215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic changes in therapy-related MDS/AML.
    Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
    Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome.
    Fan R; Zhang LY; Wang H; Yang B; Han T; Zhao XL; Wang W; Wang XQ; Lin GW
    Tohoku J Exp Med; 2012 Jun; 227(2):119-28. PubMed ID: 22706399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between IL-7 genomic protein methylation level and acute myeloid leukemia.
    Li ZH; Liu Y; Gao SY
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1196-1202. PubMed ID: 30779089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
    Aggerholm A; Holm MS; Guldberg P; Olesen LH; Hokland P
    Eur J Haematol; 2006 Jan; 76(1):23-32. PubMed ID: 16343268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML.
    Treppendahl MB; Qiu X; Søgaard A; Yang X; Nandrup-Bus C; Hother C; Andersen MK; Kjeldsen L; Möllgård L; Hellström-Lindberg E; Jendholm J; Porse BT; Jones PA; Liang G; Grønbæk K
    Blood; 2012 Jan; 119(1):206-16. PubMed ID: 22058117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic deletions in AML and MDS.
    Ebert BL
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm.
    Zhang TJ; Xu ZJ; Wen XM; Gu Y; Ma JC; Yuan Q; Lin J; Zhou JD; Qian J
    Leukemia; 2022 Oct; 36(10):2488-2498. PubMed ID: 35906386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
    Benetatos L; Hatzimichael E; Dasoula A; Dranitsaris G; Tsiara S; Syrrou M; Georgiou I; Bourantas KL
    Leuk Res; 2010 Feb; 34(2):148-53. PubMed ID: 19595458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
    Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
    Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders.
    Neuman WL; Rubin CM; Rios RB; Larson RA; Le Beau MM; Rowley JD; Vardiman JW; Schwartz JL; Farber RA
    Blood; 1992 Mar; 79(6):1501-10. PubMed ID: 1347709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-related epigenetic drift in the pathogenesis of MDS and AML.
    Maegawa S; Gough SM; Watanabe-Okochi N; Lu Y; Zhang N; Castoro RJ; Estecio MR; Jelinek J; Liang S; Kitamura T; Aplan PD; Issa JP
    Genome Res; 2014 Apr; 24(4):580-91. PubMed ID: 24414704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5q-, twenty-five years later: a synopsis.
    Van den Berghe H; Michaux L
    Cancer Genet Cytogenet; 1997 Mar; 94(1):1-7. PubMed ID: 9078284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.
    Paul TA; Bies J; Small D; Wolff L
    Blood; 2010 Apr; 115(15):3098-108. PubMed ID: 20190193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.